Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
| Status: | Archived |
|---|---|
| Conditions: | Liver Cancer, Cancer, Gastrointestinal, Digestive Disease |
| Therapuetic Areas: | Gastroenterology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | January 2010 |
The primary objective of this study is to assess the overall survival (OS) of oral linifanib
given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per
standard of care in subjects with advanced or metastatic HCC.
We found this trial at
13
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials